CC-5013 en es it fr

CC-5013 Brand names, CC-5013 Analogs

CC-5013 Brand Names Mixture

  • No information avaliable

CC-5013 Chemical_Formula


CC-5013 RX_link

CC-5013 fda sheet

CC-5013 FDA

CC-5013 msds (material safety sheet)

CC-5013 Synthesis Reference

No information avaliable

CC-5013 Molecular Weight

252.268 g/mol

CC-5013 Melting Point

215.5 oC

CC-5013 H2O Solubility

308 mg/L at 25 oC (SRC PhysProp estimated -- MEYLAN,WM et al. (1996))

CC-5013 State


CC-5013 LogP


CC-5013 Dosage Forms

Suspension; Tablet (150 mg, 300 mg and 600 mg film coated)

CC-5013 Indication

For use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy.

CC-5013 Pharmacology

Oxcarbazepine is structurally a derivative of carbamazepine, adding an extra oxygen atom to the benzylcarboxamide group. This difference helps reduce the impact on the liver of metabolizing the drug, and also prevents the serious forms of anemia occasionally associated with carbamazepine. Aside from this reduction in side effects, it is thought to have the same mechanism as carbamazepine - sodium channel inhibition - and is generally used to treat the same conditions.

CC-5013 Absorption

Completely absorbed following oral administration. Food has no effect on the rate and extent of absorption of oxcarbazepine.

CC-5013 side effects and Toxicity

Isolated cases of overdose with oxcarbazepine have been reported. The maximum dose taken was approximately 24,000 mg. All patients recovered with symptomatic treatment.

CC-5013 Patient Information

CC-5013 Organisms Affected

Humans and other mammals